PARTNERSHIP
Zeumed x ULAM Labs
Designing digital health products that can be funded, adopted and scaled
Zeumed and ULAM Labs partner to help digital health and medtech teams design products that make sense clinically, technically, and commercially.
We work with founders and scale-ups who need more than great software: they need a clear route through payer decision-making, procurement, and funding, without discovering too late that key assumptions don’t hold.
WHY THIS PARTNERSHIP EXISTS
The problem we address together
Many digital health products work well in pilots, but struggle to move beyond them. Reasons include unclear or unrealistic funding routes, evidence that doesn't match what decision-makers need, and product designs that don't fit real clinical workflows or purchasing constraints.
These issues are rarely about effort or quality. They arise because commercial, clinical, and technical decisions are often made separately, and too late.
ZEUMED LEADS
Commercial & economic design
Reimbursement strategy, evidence requirements, funding pathway design, and payer logic — ensuring the commercial and economic case is built into the product from the start, not retrofitted at submission.
ULAM LABS LEADS
Product design & engineering
Custom software development specialising in healthcare — building products that are technically sound, clinically usable, and designed for the real constraints of institutional healthcare markets.
THE APPROACH
An integrated economic and technical design approach
In institutional healthcare markets, adoption depends on how products fit within funding, procurement, and care-delivery structures. Clinical value and technical performance are essential, but not sufficient on their own.
Through a joint Zeumed × ULAM Labs approach, economic viability, clinical use-case design, and technical architecture are developed in parallel. Assumptions about who pays, how value is assessed, and what evidence is required are reflected directly in product scope, data capture, and system design — rather than addressed retrospectively.
The aim is straightforward: reduce the risk that a product needs to be rethought once it reaches payers, providers, or procurement teams.
WHAT THE ENGAGEMENT PRODUCES
Strategic Deliverables
Product - Market - Payer Fit Assessment
Analysis of whether the product addresses a funded need — who decides, on what basis, and what that implies for scope and design.
Pricing & Reimbursement Strategy
Pathway analysis across relevant payer systems: funding routes, pricing frameworks, and the conditions attached to each
Technical and Clinical Roadmap
Development plan with reimbursement and evidence milestones built in from the start, not appended after engineering decisions are made.
Evidence Generation Plan
Study design and data strategy aligned to what decision-makers require — not only what is feasible to collect.
TIMING
When to engage
Earlier engagement produces better outcomes. The value of integrating economics and product development depends on decisions still being reversible.
Before clinical trials
Reimbursement strategy should inform what is measured in a trial — not follow from it.
New markets or indications
Expansion requires a new commercial and economic case — existing evidence rarely transfers directly.
During MVP development
Product decisions are still reversible — payer requirements can be built in from the outset.
Before the next funding round
Investors will expect a credible reimbursement narrative alongside clinical results.
WHO THIS IS FOR
This partnership is suited to teams who:
Are building digital health or medtech products intended for institutional buyers
Are moving from concept to pilot, or from pilot to scale
Need clarity on funding, pricing, or reimbursement routes
Want product decisions to stand up to payer, provider, and investor scrutiny
Get in Touch
To discuss how Zeumed and ULAM Labs can support your product development and market access journey, and find out more about our workshops.